Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-QRS-Based Assessment of Compound Danshen Dripping Pills for Coronary Microcirculatory Disease (HANDS)
ChiCTR2500109076Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Compound Danshen in Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: HyperQ myocardial ischemia improvement rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Compound Danshen
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2500109076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109076.